



Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference

July 20, 2023

WALTHAM, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will present on behalf of the company at the virtual H.C. Wainwright 2nd Annual Kidney Conference on Tuesday, July 25, 2023 at 2:00 P.M. Eastern Time.

To access the live webcast of the presentation, please visit the Events and Presentations page within the Ardelyx website at <https://ir.ardelyx.com/events-and-presentations>. A replay of the presentation will be available on the Ardelyx website for 30 days following the event.

About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA[®] (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH[®] (tenapanor), a novel product candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories. For more information, please visit <https://ardelyx.com/> and connect with us on [Twitter](#), [LinkedIn](#) and [Facebook](#).

Investor and Media Contacts:

Caitlin Lowie

clowie@ardelyx.com

Kimia Keshtbod

kkeshtbod@ardelyx.com



Source: Ardelyx, Inc.